Cited by 267Ultrasound and Hyperthermia ApplicationsNanoparticle-Based Drug DeliveryNanoplatforms for cancer theranostics

Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model

Open access
Ranjan, Ashish, Jacobs, Genevieve C., Woods, David L., Negussie, Ayele H., Partanen, Ari, Yarmolenko, Pavel S., Gacchina, Carmen E., Sharma, Karun V. +3 more·2012·Journal of Controlled Release

Abstract

Clinical-grade doxorubicin encapsulated low temperature sensitive liposomes (LTSLs) were combined with a clinical magnetic resonance-guided high intensity focused ultrasound (MR-HIFU) platform to investigate in vivo image-guided drug delivery. Plasma pharmacokinetics were determined in 3 rabbits. Fifteen rabbits with Vx2 tumors within superficial thigh muscle were randomly assigned into three treatment groups: 1) free doxorubicin, 2) LTSL and 3) LTSL + MR-HIFU. For the LTSL + MR-HIFU group, mild hyperthermia (40-41 °C) was applied to the tumors using an MR-HIFU system. Image-guided non-invasive hyperthermia was applied for a total of 30 min, completed within 1h after LTSL infusion. High-pressure liquid chromatography (HPLC) analysis of the harvested tumor and organ/tissue homogenates was performed to determine doxorubicin concentration. Fluorescence microscopy was performed to determine doxorubicin spatial distribution in the tumors. Sonication of Vx2 tumors resulted in accurate (mean = 40.5 ± 0.1 °C) and spatially homogenous (SD = 1.0 °C) temperature control in the target region. LTSL + MR-HIFU resulted in significantly higher tumor doxorubicin concentrations (7.6- and 3.4-fold greater compared to free doxorubicin and LTSL respectively, p<0.05, Newman-Keuls). This improved tumor concentration was achieved despite heating <25% of the tumor volume. Free doxorubicin and LTSL treatments appeared to deliver more drug in the tumor periphery as compared to the tumor core. In contrast, LTSL + MR-HIFU treatment suggested an improved distribution with doxorubicin found in both the tumor periphery and core. Doxorubicin bio-distribution in non-tumor organs/tissues was fairly similar between treatment groups. This technique has potential for clinical translation as an image-guided method to deliver drug to a solid tumor.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2011.12.011

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ranjan, A., Jacobs, G. C., Woods, D. L., Negussie, A. H., Partanen, A., Yarmolenko, P. S., Gacchina, C. E., Sharma, K. V., Frenkel, V., Wood, B. J., & Dreher, M. R.
Affiliations
  • National Institutes of Health (US)
  • Catholic University of America (US)
Corresponding author
Dreher, Matthew R.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2012-03
Volume
158
Issue
3
Pages
487-494
ISSN
0168-3659 (ISSN-L)
OpenAlex
W1982194007
Cited by
267
References
44
Citations by year
2026: 5 · 2025: 3 · 2024: 11 · 2023: 14 · 2022: 12 · 2021: 17 · 2020: 12 · 2019: 15 · 2018: 18 · 2017: 20 · 2016: 38 · 2015: 28 · 2014: 30 · 2013: 30 · 2012: 13
FWCI
13.80
Type
journal article
Language
en
Open access
Locations
  • Journal of Controlled Release (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
Center for Interventional Oncology in the Intramural Research Program of the National Institutes of Health
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
Keywords
image-guided drug delivery, MR-guided focused ultrasound, thermosensitive liposomes, doxorubicin, cancer hyperthermia, VX2 tumor model, plasma pharmacokinetics, drug biodistribution
MeSH terms
Animals, Doxorubicin, Female, Liposomes, Neoplasms, Magnetic Resonance Spectroscopy, Rabbits, Temperature, Tissue Distribution, Ultrasonography, Drug Delivery Systems, High-Intensity Focused Ultrasound Ablation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review